Emergent Announces Plans for TRU-016 Program Following Termination of Collaboration with Abbott

Emergent BioSolutions Inc. (NYSE: EBS) today announced plans for its TRU-016 program following receipt of a notice from Abbott (NYSE: ABT) that it is terminating its co-development and co-commercialization agreement. Abbott's decision is a result of the company's portfolio prioritization process.

TRU-016, Emergent's humanized anti-CD37 mono-specific protein therapeutic, recently commenced a Phase 2 clinical study for chronic lymphocytic leukemia and is currently in the middle of Phase 1b clinical evaluation in non-Hodgkin's lymphoma. These studies will be completed, and final study data will be available by 1H 2013.